Accendra Health Inc (ACH)

Accendra Health Announces Expiration and Final Results of Offers and Consent SolicitationsJune 23, 2026 9:15 PM
Business Wire Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). As of 5:00 P.M., New York City time, on June 23, 2026 (the “Expiration Time”), the Company received from Eligible Holders valid and unwithdrawn tenders and related Consents (as defined below), as reported by Epiq Corporate Restructuring, LLC (the “Exchange Agent” and “Information Agent”), representing approximately $478.3 million and $548.0 million in aggregate principal amount of 2029 Notes and 2030 Notes, respectively, or approximately 99.9% and 99.2% of the aggregate principal amount of 2029 Notes and 2030 Notes outstanding at the launch of the Exchange Offers, respectively. The Company’s obligation to accept for exchange Existing Notes validly tendered (and not validly withdrawn) pursuant to the Exchange Offers is subject to the satisfaction or, if permitted, waiver of, certain conditions set forth in the confidential offering memorandum and consent solicitation statement, dated May 22, 2026 (the “Offering Memorandum”). Capitalized terms used herein, but not otherwise defined, have the meanings ascribed to such terms in the Offering Memorandum. In connection with the Exchange Offers, the Company issued or expects to issue a total of: (i) $213.0 million in aggregate principal amount of First Lien Notes and (ii) $698.1 million in aggregate principal amount of Second Lien Notes, in exchange for the validly tendered and accepted Existing Notes, and issued $326.25 million in aggregate principal amount of First Lien Notes in the New Money Notes Issuance, for a total of $539.25 million First Lien Notes. The offering of the New Notes has not been registered with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), or any state or foreign securities laws. The Exchange Offers were only made to holders of Existing Notes that are (a) reasonably believed to be qualified institutional buyers in reliance on Rule 144A promulgated under the Securities Act or (b) non-U.S. persons, in transactions outside the United States, in reliance on Regulation S under the Securities Act (such holders, the “Eligible Holders”). Epiq Corporate Restructuring, LLC has been appointed as the Exchange Agent and the Information Agent for the Offers and Consent Solicitations. Questions concerning the Offers and the Consent Solicitations may be directed to the Exchange Agent and Information Agent, in accordance with the contact details shown on the back cover of the Offering Memorandum. Ducera Securities LLC has been engaged to act as our financial advisor for the Offers and Consent Solicitations. No Offer or Solicitation This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Offers and Consent Solicitations, or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this press release is not an offer of securities for sale into the United States. The New Notes offered in the Offers have not been registered under the Securities Act or any state securities laws, and unless so registered, New Notes may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. About Accendra Health Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding our expectations regarding the Offers and Consent Solicitations, the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. The Company cautions readers of this communication that such “forward-looking statements,” wherever they occur in this communication or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward-looking statements.” Factors that could cause the Company’s actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the “Risk Factors” sections of our most recent Annual Report on Form 10-K for the period ended December 31, 2025, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Current Report on Form 8-K and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. ACH-CORP ACH-IR View source version on businesswire.com: https://www.businesswire.com/news/home/20260623793524/en/ Investors
Will Parrish
Vice President, Strategy, Corporate Development, & Investor Relations
Investor.Relations@accendra.com Original: Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations

Accendra Health Announces Early Results of Offers and Consent SolicitationsJune 10, 2026 6:30 AM
Business Wire Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the early results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). Eligible Holders of 2029 Notes that participate in the New Money Notes Issuance (as defined below) will be able to exchange such 2029 Notes for newly issued 9.000% Senior Secured First Lien Notes due 2032 (the “First Lien Notes”) and newly issued 9.750% Senior Secured Second Lien Notes due 2033 (the “Second Lien Notes” and, together with the First Lien Notes, the “New Notes”). Eligible Holders of 2029 Notes that do not participate in the New Money Notes Issuance and Eligible Holders of 2030 Notes will be able to exchange such notes for Second Lien Notes. As of 5:00 P.M., New York City time, on June 9, 2026 (the “Early Exchange Time”), the Company received from Eligible Holders valid and unwithdrawn tenders and related Consents (as defined below), as reported by Epiq Corporate Restructuring, LLC (the “Exchange Agent” and “Information Agent”), representing approximately $478.3 million and $547.9 million in aggregate principal amount of 2029 Notes and 2030 Notes, respectively, or approximately 99.9% and 99.2% of the aggregate principal amount of 2029 Notes and 2030 Notes outstanding, respectively. In addition, as of the Early Exchange Time, the Company received the requisite consents (the “Consents”) in its concurrent consent solicitations (the “Consent Solicitations”) from Eligible Holders of the Existing Notes to adopt certain proposed amendments to the indentures governing each series of the Existing Notes (the “Existing Notes Indentures”) to eliminate substantially all of the affirmative and negative covenants, eliminate certain events of default, modify covenants regarding mergers and consolidations and modify or eliminate certain other provisions contained in each of the Existing Notes Indentures, including provisions related to defeasance (collectively, the “Proposed Amendments”). The Company has entered into supplemental indentures with the trustees for the Existing Notes and the guarantors party thereto to give effect to the Proposed Amendments, which will become operative as of the Early Settlement Date. In connection with the Exchange Offer for the 2029 Notes, the Company also offered $326.25 million in aggregate principal amount of newly issued First Lien Notes for cash (the “New Money Notes Issuance” and, together with the Exchange Offers, collectively, the “Offers”). The New Notes will be issued by the Company and guaranteed on a senior secured basis by the Company’s existing and future wholly owned domestic subsidiaries (including each subsidiary guarantor of the Existing Notes). To be eligible to receive the New Money Participant Early Exchange Consideration, each Eligible Holder of 2029 Notes (other than the Backstop Parties (as defined below)) was required to tender all of its 2029 Notes at or prior to the Early Exchange Time and must deliver in cash their pro rata cash portion of $65.25 million in aggregate principal amount of First Lien Notes to the Exchange Agent by 5:00 P.M., New York City time, on June 10, 2026, unless extended (such time and date as it may be extended, the “Funding Date”). As previously announced, pursuant to a Commitment and Consent Letter (the “Commitment Agreement”), dated as of May 11, 2026, by and among the Company, certain holders of Existing Notes and certain of the Company’s existing lenders (collectively, the “Commitment Parties”), the Backstop Parties have agreed to purchase (i) their agreed percentage of an aggregate principal amount of $261.0 million of the New Money First Lien Notes, at a price equal to par, and (ii) up to an additional $65.25 million of First Lien Notes, at a price equal to par, to the extent such amount is not purchased in the New Money Notes Issuance by Eligible Holders of the 2029 Notes who are not Backstop Parties, subject to the consummation of the Offers and Consent Solicitations and the satisfaction of certain other conditions. Eligible Holders of 2029 Notes electing to participate in the Exchange Offer for 2029 Notes will receive different Exchange Consideration depending on their participant category: (a) Eligible Holders of 2029 Notes who elected to purchase their pro rata cash portion of New Money First Lien Notes by the Funding Date are referred to herein as “New Money Participants,” (b) Eligible Holders of 2029 Notes who are Backstop Parties under the Commitment Agreement and tender their committed 2029 Notes are referred to herein as “Backstop Participants” and (c) Eligible Holders of 2029 Notes who are neither New Money Participants nor Backstop Participants are referred to herein as “Other Eligible Participants.” All Eligible Holders of 2030 Notes will receive the same Exchange Consideration regardless of participant category. As of the Early Exchange Time, approximately $124.0 million in aggregate principal amount of 2029 Notes were tendered by New Money Participants (subject to payment of the New Money Notes Purchase Price by the Funding Date, as applicable), approximately $332.0 million in aggregate principal amount of 2029 Notes were tendered by Backstop Participants and approximately $22.3 million in aggregate principal amount of 2029 Notes were tendered by Other Eligible Participants. Each participating Eligible Holder must tender all of the Existing Notes it holds through The Depository Trust Company’s (“DTC”) Automated Tender Offer Program (“ATOP”). The Company’s obligation to accept for exchange Existing Notes validly tendered (and not validly withdrawn) and to complete the New Money Notes Issuance pursuant to the Offers and related Consent Solicitations is subject to the satisfaction or, if permitted, waiver of, certain conditions set forth in the confidential offering memorandum and consent solicitation statement, dated May 22, 2026 (the “Offering Memorandum”). Capitalized terms used herein, but not otherwise defined, have the meanings ascribed to such terms in the Offering Memorandum. As of 5:00 P.M., New York City time, on June 9, 2026, the right to withdraw tenders of Existing Notes and related Consents expired. Accordingly, Existing Notes tendered for exchange at or before such time may not be validly withdrawn and Consents may no longer be revoked, unless required by applicable law or the Company determines in the future in its sole discretion to permit withdrawal and revocation rights. The Company further announced an amendment to the Offers, whereby the expected Early Settlement Date with respect to all Existing Notes tendered at or prior to the Early Exchange Time is expected to be June 15, 2026. Additionally, the Expiration Time has been extended to 5:00 P.M., New York City time, on June 23, 2026 and the Late Settlement Date is expected to be June 25, 2026. The New Notes and the offering thereof have not been registered with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), or any state or foreign securities laws. The Offers and Consent Solicitations are only being made, and the New Notes are only being offered and issued, to holders of Existing Notes that are (a) reasonably believed to be qualified institutional buyers in reliance on Rule 144A promulgated under the Securities Act or (b) non-U.S. persons, in transactions outside the United States, in reliance on Regulation S under the Securities Act (such holders, the “Eligible Holders”). Only Eligible Holders are authorized to receive or review the Offering Memorandum and to participate in the Offers. Copies of all the documents relating to the Offers and Consent Solicitations may be obtained from the Exchange Agent and Information Agent, subject to confirmation of eligibility through online procedures established by the Exchange Agent and Information Agent, by completing the Eligibility Letter at https://epiqworkflow.com/cases/AccendraEligibility or via email submission of the Eligibility Letter to Registration@epiqglobal.com, with a reference to “ACCENDRA” in the subject line. There will be no letter of transmittal for the Exchange Offers. The Offers are being made solely by the Offering Memorandum. Eligible Holders of the Existing Notes are urged to carefully read all of the information in, or incorporated by reference into, the Offering Memorandum, including the information presented under “Risk Factors” and “Forward-Looking Statements” before making any decision with respect to the Offers or the Consent Solicitations. None of the Company, its subsidiaries, the Exchange Agent, the Information Agent, the trustees under the Existing Notes Indentures and the indentures that will govern the New Notes, the collateral agents under the indentures that will govern the New Notes or any of their respective affiliates, makes any recommendation as to whether holders of Existing Notes should participate in the Offers or Consent Solicitations. Each Eligible Holder must make its own decision as to whether to participate in the Offers and whether to tender its Existing Notes and to deliver Consents. Epiq Corporate Restructuring, LLC has been appointed as the Exchange Agent and the Information Agent for the Offers and Consent Solicitations. Questions concerning the Offers and the Consent Solicitations may be directed to the Exchange Agent and Information Agent, in accordance with the contact details shown on the back cover of the Offering Memorandum. Ducera Securities LLC has been engaged to act as our financial advisor for the Offers and Consent Solicitations. No Offer or Solicitation This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Offers and Consent Solicitations, or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this press release is not an offer of securities for sale into the United States. The New Notes offered in the Offers have not been registered under the Securities Act or any state securities laws, and unless so registered, New Notes may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. About Accendra Health Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding our expectations regarding the Offers and Consent Solicitations, the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. The Company cautions readers of this communication that such “forward-looking statements,” wherever they occur in this communication or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward-looking statements.” Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction; the failure to satisfy other conditions to completion of the transaction; risks related to disruption of management’s attention from the Company’s ongoing business operations due to the transaction; the effect of the announcement of the transaction on the Company’s relationships with its customers, suppliers and other third parties, as well as its operating results and business generally; the risk that the transaction will not be consummated in a timely manner; exceeding the expected costs of the transaction; and risks related to the Commitment Parties’ committed financing. Additional factors that could cause the Company’s actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the “Risk Factors” sections of our most recent Annual Report on Form 10-K for the period ended December 31, 2025, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Current Report on Form 8-K and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. ACH-CORP ACH-IR View source version on businesswire.com: https://www.businesswire.com/news/home/20260610686582/en/ Investors
Will Parrish
Vice President, Strategy, Corporate Development, & Investor Relations
Investor.Relations@accendra.com Original: Accendra Health Announces Early Results of Offers and Consent Solicitations

Accendra Health (ACH) Shares Jump After First-Quarter Earnings BeatMay 11, 2026 10:14 AM
IH Market News Accendra Health, Inc. (NYSE:ACH) shares surged nearly 10% in premarket trading on Monday after the home-based healthcare company reported first-quarter 2026 earnings that came in ahead of analyst expectations.The company posted an adjusted loss of $0.04 per share for the quarter ended March 31, 2026, outperforming consensus forecasts for a loss of $0.10 per share. Revenue Misses Expectations Amid Ongoing Transformation Quarterly revenue totaled $627.8 million, below analyst expectations of $646.24 million and down 6.8% from $673.9 million in the same period last year.On a GAAP basis, Accendra reported a loss from continuing operations of $0.08 per share, compared with a loss of $0.05 per share in the first quarter of 2025.Adjusted EBITDA declined to $58.4 million from $96.0 million in the prior-year quarter.“Our first quarter results were aligned with our expectations as we continue our transformation into a pure play home based care company,” said President and Chief Executive Officer Edward A. Pesicka. “We are also pleased to report that transition services and other separation activity related to our divestiture of Owens & Minor are on track and going according to schedule.” Company Announces Major Balance Sheet Optimization Plan Accendra also revealed that it has secured commitments from existing creditors for a balance sheet optimization transaction valued at more than $1.5 billion.According to the company, the refinancing initiative is expected to strengthen its financial position, extend debt maturities and lower overall leverage.The transaction includes plans to repay debt maturing in 2027 and extend the company’s revolving credit facility. Full-Year Guidance Reaffirmed Despite the revenue shortfall, Accendra maintained its previously issued full-year 2026 guidance for both net revenue and adjusted EBITDA.Accendra Health stock price Original: Accendra Health (ACH) Shares Jump After First-Quarter Earnings Beat

Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization TransactionMay 11, 2026 6:30 AM
Business Wire Commitments in Place from Existing Creditors to Strengthen Balance Sheet, Extend Maturities, and Reduce Leverage Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive balance sheet optimization transaction with commitments from existing creditors that will strengthen the balance sheet, significantly extend maturities and reduce total leverage. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Our first quarter results were aligned with our expectations as we continue our transformation into a pure play home based care company. We are also pleased to report that transition services and other separation activity related to our divestiture of Owens & Minor are on track and going according to schedule,” said Edward A. Pesicka, President & Chief Executive Officer, Accendra Health. “Also, this morning we announced the receipt of commitments from existing creditors that will allow us to conduct a holistic reset of our capital structure and establish the long-term foundation for Accendra Health. Key benefits include paying off our 2027 maturities, a multi-year extension of our revolving credit facility, meaningful debt reduction, and other maturity extensions. This comprehensive solution should provide the business with the appropriate level of liquidity and allows for strategic and financial flexibility for our future,” Pesicka concluded. The Company plans to effectuate the balance sheet optimization transaction in the near term. Further details on the transactions are available in supplemental slides included on Form 8-K filed with the Securities & Exchange Commission this morning. Details on First Quarter 2026 Results First Quarter Results(1)             ($ in millions, except per share data)   1Q26   1Q25               Net Revenue   $ 627.8     $ 673.9                 Loss from continuing operations, net of tax, GAAP   $ (6.5 )   $ (3.8 ) Adj. net (loss) income from continuing operations, Non-GAAP   $ (3.1 )   $ 23.2                 Adj. EBITDA, Non-GAAP   $ 58.4     $ 96.0   Free cash flow, Non-GAAP   $ (2.0 )   $ 35.6                 Loss from continuing operations, net of tax per common share, GAAP   $ (0.08 )   $ (0.05 ) Adj. net (loss) income from continuing operations per share, Non-GAAP   $ (0.04 )   $ 0.29   (1) Reconciliations of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are included in the tables below. 2026 Continuing Operations Financial Outlook The company is affirming its prior guidance for net revenue and adjusted EBITDA for the full year 2026. Although the Company provides guidance for adjusted EBITDA (which is a non-GAAP financial measure), it is not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP without unreasonable effort. Certain elements of the composition of the GAAP amounts are not predictable, making it impracticable for the Company to forecast. Such elements include, but are not limited to, restructuring and acquisition charges which could have a significant and unpredictable impact on our GAAP results. As a result, no GAAP guidance or reconciliation of the Company’s adjusted EBITDA guidance is provided. The outlook is based on certain assumptions, including, but not limited to, market conditions, consumer demand, supply chain stability, interest rates, and other factors that are subject to the risk factors discussed in the Company’s filings with the SEC. Investor Conference Call for First Quarter 2026 Financial Results Accendra Health will host a conference call for investors and analysts on Monday, May 11, 2026, at 8:30 a.m. E.T. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendrahealth.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above. Safe Harbor This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2026 financial results, our expectations regarding the performance of our business following the completion of the sale of the Products & Healthcare Services business, the adverse impact of failing to consummate all or part of the balance sheet optimization transaction on the terms described herein or at all, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. About Accendra Health Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology and ostomy, visit www.accendrahealth.com.   Accendra Health, Inc.
Condensed Consolidated Statements of Operations (unaudited)
(dollars in thousands, except per share data)                   Three Months Ended March 31,     2026   2025 Net revenue   $ 627,780     $ 673,884   Operating costs and expenses:             Cost of net revenue     349,752       354,642   Selling, general and administrative expenses     255,226       262,370   Acquisition-related charges and intangible amortization     29,229       23,456   Exit and realignment (income) charges, net     (23,552 )     13,625   Total operating costs and expenses     610,655       654,093   Operating income     17,125       19,791   Interest expense, net     32,348       24,214   Other expense, net     1,023       975   Loss from continuing operations before income taxes     (16,246 )     (5,398 ) Income tax benefit     (9,778 )     (1,588 ) Loss from continuing operations, net of tax     (6,468 )     (3,810 ) Loss from discontinued operations, net of tax     —       (21,172 ) Net loss   $ (6,468 )   $ (24,982 )               Basic loss per common share             Loss from continuing operations, net of tax   $ (0.08 )   $ (0.05 ) Loss from discontinued operations, net of tax     —       (0.27 ) Net loss   $ (0.08 )   $ (0.32 )               Diluted loss per common share             Loss from continuing operations, net of tax   $ (0.08 )   $ (0.05 ) Loss from discontinued operations, net of tax     —       (0.27 ) Net loss   $ (0.08 )   $ (0.32 )   Accendra Health, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(dollars in thousands)                   March 31, 2026   December 31, 2025 Assets             Current assets             Cash and cash equivalents   $ 336,880     $ 281,989   Accounts receivable, net     103,703       95,907   Inventories, net     65,285       74,435   Other current assets     82,632       95,540   Total current assets     588,500       547,871   Patient service equipment and other fixed assets, net of accumulated depreciation and amortization of $180,939 and $207,595     227,732       256,161   Operating lease assets     101,967       109,099   Goodwill     1,228,140       1,228,140   Intangible assets, net     107,236       136,465   Other assets, net     162,407       174,025   Total assets   $ 2,415,982     $ 2,451,761   Liabilities and deficit             Current liabilities             Accounts payable   $ 374,824     $ 363,565   Accrued payroll and related liabilities     33,403       69,426   Current portion of long-term debt     581,250       250,000   Other current liabilities     213,627       264,084   Total current liabilities     1,203,104       947,075   Long-term debt, excluding current portion     1,521,941       1,799,876   Operating lease liabilities, excluding current portion     67,466       70,317   Other liabilities     88,236       95,471   Total liabilities     2,880,747       2,912,739   Total deficit     (464,765 )     (460,978 ) Total liabilities and deficit   $ 2,415,982     $ 2,451,761     Accendra Health, Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(dollars in thousands)                   Three Months Ended March 31,     2026   2025 Operating activities:             Net loss   $ (6,468 )   $ (24,982 ) Loss from discontinued operations, net of tax     —       21,172   Adjustments to reconcile net loss to cash used for operating activities:             Depreciation and amortization     61,742       42,902   Share-based compensation expense     3,090       4,421   Deferred income tax expense (benefit)     2,571       (4,395 ) Changes in operating lease right-of-use assets and lease liabilities     122       827   Gain from sale and dispositions of patient service equipment     (55,509 )     (5,353 ) Changes in operating assets and liabilities:             Accounts receivable, net     (7,796 )     4,745   Inventories, net     9,150       (6,319 ) Accounts payable     8,775       16,124   Net change in other assets and liabilities     (69,174 )     (18,065 ) Other, net     3,420       401   Cash used for operating activities from discontinued operations     —       (66,544 ) Cash used for operating activities     (50,077 )     (35,066 ) Investing activities:             Additions to patient service equipment ($41,343 and $44,484) and other fixed assets     (41,646 )     (45,793 ) Proceeds from sale of patient service equipment     96,415       16,884   Additions to computer software     (844 )     (2,329 ) Other, net     —       (410 ) Cash used for investing activities from discontinued operations     —       (16,552 ) Cash provided by (used for) investing activities     53,925       (48,200 ) Financing activities:             Borrowings under Revolving Credit Facility     269,100       776,984   Repayments under Revolving Credit Facility     (217,600 )     (679,484 ) Repurchase of common stock     —       (1,503 ) Other, net     (416 )     (146 ) Cash used for financing activities from discontinued operations     —       (3,073 ) Cash provided by financing activities     51,084       92,778   Effect of exchange rate changes on cash and cash equivalents     (41 )     542   Net increase in cash and cash equivalents     54,891       10,054   Cash and cash equivalents at beginning of period     281,989       49,382   Cash and cash equivalents at end of period   $ 336,880     $ 59,436   Supplemental disclosure of cash flow information:             Income taxes paid, net   $ 20,042     $ 125   Interest paid   $ 29,446     $ 27,487   Noncash investing activity:             Unpaid purchases of patient service equipment and other fixed assets at end of period   $ 71,997     $ 81,085     Accendra Health, Inc.
Net Loss Per Common Share (unaudited)
(dollars in thousands, except per share data)                   Three Months Ended March 31,     2026   2025 Loss from continuing operations, net of tax   $ (6,468 )   $ (3,810 ) Loss from discontinued operations, net of tax     —       (21,172 ) Net loss   $ (6,468 )   $ (24,982 )               Weighted average shares outstanding - basic     76,432       77,272   Dilutive shares     —       —   Weighted average shares outstanding - diluted     76,432       77,272                 Basic loss per common share             Loss from continuing operations, net of tax   $ (0.08 )   $ (0.05 ) Loss from discontinued operations, net of tax     —       (0.27 ) Net loss   $ (0.08 )   $ (0.32 )               Diluted loss per common share:             Loss from continuing operations, net of tax   $ (0.08 )   $ (0.05 ) Loss from discontinued operations, net of tax     —       (0.27 ) Net loss   $ (0.08 )   $ (0.32 )   Share-based awards for the three months ended March 31, 2026 and 2025 of approximately 1.3 million and 1.8 million shares were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive.   Accendra Health, Inc.
GAAP/Non-GAAP Reconciliations (unaudited)
(dollars in thousands, except per share data)   The following table provides a reconciliation of reported loss from continuing operations, net of tax and loss from continuing operations per common share to non-GAAP measures used by management.                   Three Months Ended March 31,     2026   2025 Loss from continuing operations, net of tax, as reported (GAAP)   $ (6,468 )   $ (3,810 ) Pre-tax adjustments:             Acquisition-related charges and intangible amortization (1)     29,229       23,456   Exit and realignment (income) charges, net (2)     (23,552 )     13,625   Litigation and related charges (3)     64       270   Other (6)     409       424   Income tax benefit on pre-tax adjustments (8)     (2,828 )     (10,732 ) (Loss) income from continuing operations, net of tax, adjusted (non-GAAP) (Adjusted Net Income)   $ (3,146 )   $ 23,233                 Loss from continuing operations, net of tax per common share, as reported (GAAP)   $ (0.08 )   $ (0.05 ) After-tax adjustments:             Acquisition-related charges and intangible amortization (1)     0.20       0.22   Exit and realignment (income) charges, net (2)     (0.16 )     0.12   Litigation and related charges (3)     —       —   Other (6)     —       —   (Loss) income from continuing operations, net of tax, per common share, adjusted (non-GAAP) (Adjusted EPS)   $ (0.04 )   $ 0.29     Accendra Health, Inc.
GAAP/Non-GAAP Reconciliations (unaudited), continued
(dollars in thousands)   The following tables provide reconciliations of loss from continuing operations, net of tax and total debt to non-GAAP measures used by management.                   Three Months Ended March 31,     2026   2025 Loss from continuing operations, net of tax, as reported (GAAP)   $ (6,468 )   $ (3,810 ) Income tax benefit     (9,778 )     (1,588 ) Interest expense, net     32,348       24,214   Acquisition-related charges and intangible amortization (1)     29,229       23,456   Exit and realignment (income) charges, net (2)     (23,552 )     13,625   Litigation and related charges (3)     64       270   Other depreciation and amortization (4)     32,513       35,336   Stock compensation (5)     3,604       4,091   Other (6)     409       424   Adjusted EBITDA (non-GAAP)     58,369       96,018   Non-cash convert to sale write off expense (7)     10,416       11,531   Patient service equipment capital expenditures     (41,343 )     (44,484 ) Interest paid     (29,446 )     (27,487 ) Free cash flow (non-GAAP)   $ (2,004 )   $ 35,578     March 31,   December 31,   2026   2025 Total debt, as reported (GAAP) $ 2,103,191     $ 2,049,876   Cash and cash equivalents   (336,880 )     (281,989 ) Net debt (non-GAAP) $ 1,766,311     $ 1,767,887   The following items have been excluded in our non-GAAP financial measures: (1) Acquisition-related charges and intangible amortization for the three months ended March 31, 2025 includes $16 million of acquisition-related costs related to the terminated acquisition of Rotech, which consisted primarily of legal and professional fees. Acquisition-related charges and intangible amortization also include amortization of intangible assets established during acquisition method of accounting for business combinations. Acquisition-related charges consist primarily of one-time costs related to acquisitions, including transaction costs necessary to consummate acquisitions, such as advisory fees and legal fees, director and officer tail insurance expense, as well as transition costs, such as severance and retention bonuses, information technology (IT) integration costs and professional fees. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results. (2) During the three months ended March 31, 2026 exit and realignment (income) charges, net was $(24) million and primarily included a $(52) million gain on sales of patient service equipment in response to the contract termination with a commercial Payor, net separation costs incurred after the P&HS Sale of $26 million and charges related to IT and other strategic initiatives of $2.0 million. Exit and realignment charges, net were $14 million for the three months ended March 31, 2025 and primarily included professional fees associated with strategic initiatives of $6.2 million and wind-down costs of Fusion5 of $6.8 million. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis. (3) Litigation and related charges includes settlement costs and related charges of legal matters. These costs do not occur in the ordinary course of our business, and are inherently unpredictable in timing and amount. (4) Other depreciation and amortization relates to patient service equipment and other fixed assets, excluding such amounts captured within exit and realignment (income) charges, net or acquisition-related charges. (5) Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment (income) charges, net or acquisition-related charges and intangible amortization. (6) For the three months ended March 31, 2026 and 2025, other includes interest costs and net actuarial losses related to our frozen noncontributory, unfunded retirement plan for certain retirees in the United States (U.S.). (7) Non-cash convert to sale write off expense includes non-cash charges primarily for equipment converted from rental to sales, excluding such amounts captured within in exit & realignment (income) charges, net. This reflects the non-cash write-off of the remaining book value of patient service equipment at the time of sale. The purchase of patient service equipment is captured within capital expenditures and is subsequently charged to our statements of operations through normal depreciation and this non-cash convert to sale write off expense. This line item does not include non-cash write off expense associated with sales of patient service equipment in connection with the contract termination with a commercial Payor, as such amounts are captured within exit & realignment (income) charges, net. (8) These charges and income have been tax effected by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes. Use of Non-GAAP Measures This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, the measures exclude items and charges that (i) management does not believe reflect Accendra Health, Inc.’s (the Company) core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate the Company’s performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation. Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company’s performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated. ACH-CORP ACH-IR View source version on businesswire.com: https://www.businesswire.com/news/home/20260511344561/en/ Investors
Will Parrish
Vice President, Strategy, Corporate Development, & Investor Relations
Investor.Relations@accendra.com Media
Darla Turner
media@accendra.com Original: Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction

Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference CallMay 1, 2026 5:00 PM
Business Wire
Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the New York Stock Exchange.


The Company will host a conference call for investors and analysts at 8:30 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917.


All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendra.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.


About Accendra Health, Inc.

Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology and ostomy, visit www.accendrahealth.com.


ACH-CORP

ACH-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20260501887787/en/Investors

Will Parrish

Vice President | Strategy, Corporate Development, & Investor Relations

Investor.Relations@accendra.com


Media

Darla Turner

Media@accendra.com


Original: Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call

Schwabb filed 13G on this yesterday...someone sees value here

Accendra Health Announces Fourth Quarter 2025 Earnings Release Date and Conference CallFebruary 5, 2026 4:05 PM
Business Wire
Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange.


The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917.


All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendra.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.


About Accendra Health, Inc.


Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology and ostomy, visit www.accendrahealth.com.


ACH-CORP


ACH-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205326856/en/
Investors

Will Parrish

Vice President | Strategy, Corporate Development, & Investor Relations

Investor.Relations@accendra.com


Media

Darla Turner

Media@accendra.com


Original: Accendra Health Announces Fourth Quarter 2025 Earnings Release Date and Conference Call

What do the Long-Term Technicals Predict for Alchemy Pay ( $ACH) Friday?https://www.investorsobserver.com/news/crypto-update/what-do-the-long-term-technicals-predict-for-alchemy-pay-ach-friday

This Little-Known Altcoin Shoots Up 180% In Single Week After Series Of Updates via @newsbtc https://www.newsbtc.com/news/this-little-known-altcoin-shoots-up-180-in-single-week-after-disclosing-series-of-updates/

Ethereum Altcoin $ACH Rockets 200% in Less Than a Week As Project Ecosystem Sees Flurry of Updates https://dailyhodl.com/2023/02/22/ethereum-altcoin-rockets-200-in-less-than-a-week-as-project-ecosystem-sees-flurry-of-updates/

I just got in. YeeeeeHaaaawwwww!!!!!
Trying to figure out "why"....
Just hope and Pray it keeps going!!!

I hope you did. Floating higher daily like a balloon, it can’t stop

I just came across this stock and am thinking about taking a position. The price has dropped a lot since your last post. Hope you have a great day.

Anyone?

It is still trading, lst trade $24.08

Their site is down

What's happening with this co?

This one is flying high, no doubt!!!

Been a nice ride here since March, eh fellas?

Almost up 3 bucks today, whats goin on?

Sure was

Another nice gain today!

UPDATE: Chinalco In Talks With Rio On Board Seat, Possible Deal





(Combines comments from Chinalco official and deputy general manager, previous statement from Rio on talks with Chinalco.)


By Chuin-Wei Yap and Juan Chen
Of DOW JONES NEWSWIRES

BEIJING -(Dow Jones)- Aluminum Corp. of China Deputy General Manager Lu Youqing said Tuesday the company is in "intense" talks with Rio Tinto PLC (RTP) about a potential deal and a seat on Rio's board, signaling the Chinese mining giant wants a bigger presence in the Anglo-Australian firm.

Lu said both sides are discussing the size of the deal and the financing involved, but declined to disclose details, or confirm whether Aluminum Corp., known as Chinalco, is seeking a 15%-20% stake in Rio Tinto.

Another Chinalco official, who spoke on condition of anonymity, said earlier Tuesday Chinalco is in talks with Rio Tinto on a possible asset purchase. The official told Dow Jones Newswires "money shouldn't be a problem" for Chinalco in closing the deal.

Rio Tinto, which is looking for help to pay down some of its US$38.9 billion debt, said earlier this month it is talking with the Chinese firm on a possible sale of minority stakes in some of its mining operations and an investment in convertible instruments.

Chinalco, China's biggest aluminum producer by output, became Rio Tinto's biggest shareholder last year after it teamed up with Alcoa Inc. (AA) to pay US$14.1 billion for a 9% stake in the Rio Tinto group, which translates into a 12% stake in the listed company.

Chinalco's investment represented the biggest overseas investment by a Chinese firm on record. The Australian newspaper reported last week that the deal under discussion could be worth an estimated US$20 billion.

Chinalco has said it wouldn't seek to appoint a director to Rio Tinto PLC if it holds less than 15% of the company.

"The 12% (of Rio Tinto PLC) that Chinalco currently owns has no voting right (on the board)," said Wang Lixin, of Beijing metals consultancy Umetal.

"A deal could give Chinalco those voting rights. This is very important to Chinalco," she said.

State-controlled China Development Bank helped Chinalco on its first Rio Tinto investment last year. However, analysts are concerned that banks would be unwilling to lend funds for acquisition deals due to the financial crisis.

The Chinalco official who declined to be named also said Chinalco will appoint Xiong Weiping as chairman to replace Xiao Yaqing.

Xiao, who joined Chinalco in March 2002, will be promoted to a "more senior position" outside the company, the official said, which means Xiao would also leave his post as president of Chinalco's listed unit, Aluminum Corp. of China Ltd. (ACH), or Chalco.

Xiong, 52 years old, was a vice president of Chinalco from 2000 and left to join China Travel International Investment Hong Kong Ltd. in 2006, where he is now a vice chairman and general manager.

An official from the general manager's office of China Travel International said the company hasn't received any notice about Xiong leaving.

"Xiong is still working here now," said the official, who declined to be named. She didn't elaborate.

Chalco's shares were suspended from trading in Hong Kong and Shanghai Tuesday.

In a statement to the Hong Kong stock exchange, Chalco said its H shares were suspended pending the release of a company clarification on media reports about management changes.

-By Chuin-Wei Yap and Juan Chen; Dow Jones Newswires; 8610 6588 5848; juan.chen@dowjones.com

(Kersten Zhang of The Wall Street Journal contributed to this story.)

Very nice day, thats for sure. I hope it continues for a while.

Great gains today!!!!

I have some issues with some of these PR's. I'm not convinced they're telling it like it is, JMO
I'm still playing as long as I can


Good luck to your buddy. Tell him to roll his eyes at the drill instructor, they like that J/K


Good luck to you.

I agree, im not too big of a fan of too much hype myself. I was pretty dissapointed to hear they suspended the Madera facility but on the bright side its holding well at around .50 and I can easily see this moving up. I think it will take a little more time though.

OT: I see your a Marine! My best friend is in boot camp right now, hes already scheduled for a summer trip to Afghanistan and hes lovin it. Best of luck to you man.

LOL,
Welcome Cowboy. Most of my boards are the same, not much hype past what I post on the board. Ive come to realize too much hype kills the deal imo

Looks like you need a little company on this board, ive been in this long and im down pretty hardcore but it looks like it gaining momentum again. Good luck.

WOW!!!!!!!

Can it hit $11.00 ???

Last Price (USD) $ 10.83

Goldman Sachs picked up 133,707 shares in November !!!! gotta play with the big boys imo

ACH did good today........... back up for another round

BEIJING, Jan 13 (Reuters) - China's imports of unwrought copper and
semi-finished copper products fell 5.1 percent on the year to 2.64 million
tonnes in 2008, the General Administration of Customs said on its website on
Tuesday. (www.customs.gov.cn)
Imports surged 32 percent to 286,576 tonnes in December from 217,214
tonnes in November.
The country, the top copper and aluminium consumer in the world, exported
77,422 tonnes of unwrought aluminium in December versus 30,396 tonnes in
November. For 2008, exports rose 54.3 percent on the year to 841,292 tonnes.
(Reporting by Niu Shuping and Tom Miles) Keywords: CHINA TRADE/BASEMETALS
(polly.yam@thomsonreuters.com; +852 2843 6933; Reuters Messaging:
polly.yam.reuters.com@reuters.net)

ACH still pushing!!!!! $16.11 up 0.46

ACH $15.7301 UP 2.22
WOOOOOW!!!

ACH $15.374 +1.864

Up 30 EOD $13.51 Really nice!!!!

Up .20 in 3 minutes :)

http://ih.advfn.com/p.php?pid=nmona&cb=1230637316&article=34844703&symbol=NY%5EACH

the market will start to recover soon...within the next year we will see recovery, maybe not full recovery but we will be out of the mine field

haha well thats my preference...it may not ever happen again

hahaha I know, it seems too good to be true. I'm hoping for a dead cat bounce here...

Yeah, you are probably right, sad to say. IMO, there is going to be some very rough sleding ahead for the markets.

Seems now like everyday in the markets you are walking through a mine field. Ya just wonder when you take the next step if something is going to blow up on that day.
Pretty risky out there.

GLTA.

The way things are going these days he may not be too far off. Rough times imo

WOW!!! You want Christmas twice in one year? LOL!!!

What ever

come down to 8$ and I enter

come down to $11.50 and I re-enter :)

i hope...haha
pump money in

dead cat bounce...back to 7$